139 related articles for article (PubMed ID: 24443256)
1. Nestin: predicting specific survival factors for breast cancer.
Gao N; Xu H; Liu C; Xu H; Chen G; Wang X; Li Y; Wang Y
Tumour Biol; 2014 Mar; 35(3):1751-5. PubMed ID: 24443256
[TBL] [Abstract][Full Text] [Related]
2. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
[TBL] [Abstract][Full Text] [Related]
3. Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
Tampaki EC; Tampakis A; Nonni A; Kontzoglou K; Patsouris E; Kouraklis G
Tumour Biol; 2017 Mar; 39(3):1010428317691181. PubMed ID: 28347241
[TBL] [Abstract][Full Text] [Related]
4. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.
Buhmeida A; Dallol A; Merdad A; Al-Maghrabi J; Gari MA; Abu-Elmagd MM; Chaudhary AG; Abuzenadah AM; Nedjadi T; Ermiah E; Al-Thubaity F; Al-Qahtani MH
Tumour Biol; 2014 Mar; 35(3):2817-24. PubMed ID: 24248542
[TBL] [Abstract][Full Text] [Related]
5. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
6. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.
Zhao H; Yang M; Zhao J; Wang J; Zhang Y; Zhang Q
Med Oncol; 2013 Mar; 30(1):475. PubMed ID: 23371253
[TBL] [Abstract][Full Text] [Related]
7. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
8. Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women.
Esnakula AK; Ricks-Santi L; Kwagyan J; Kanaan YM; DeWitty RL; Wilson LL; Gold B; Frederick WA; Naab TJ
J Clin Pathol; 2014 Feb; 67(2):153-60. PubMed ID: 23986556
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
10. Impact of Expression of Vimentin and Axl in Breast Cancer.
Tanaka K; Tokunaga E; Inoue Y; Yamashita N; Saeki H; Okano S; Kitao H; Oki E; Oda Y; Maehara Y
Clin Breast Cancer; 2016 Dec; 16(6):520-526.e2. PubMed ID: 27506606
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of HOXD13 expression in human breast cancer.
Zhong ZB; Shan M; Qian C; Liu T; Shi QY; Wang J; Liu Y; Liu Y; Huang YX; Pang D
Int J Clin Exp Pathol; 2015; 8(9):11407-13. PubMed ID: 26617867
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications for nestin protein expression in breast cancer.
Liu C; Chen B; Zhu J; Zhang R; Yao F; Jin F; Xu H; Lu P
Cancer Sci; 2010 Mar; 101(3):815-9. PubMed ID: 20028381
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer.
Yao L; Chi Y; Hu X; Li S; Qiao F; Wu J; Shao ZM
Oncotarget; 2016 Aug; 7(33):53895-53902. PubMed ID: 27259993
[TBL] [Abstract][Full Text] [Related]
15. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
16. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
Chen CY; Yang CY; Chen YC; Shih CW; Lo SS; Lin CH
BMC Cancer; 2016 Aug; 16(1):697. PubMed ID: 27577936
[TBL] [Abstract][Full Text] [Related]
18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
20. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
